P3 Health Partners (NASDAQ:PIII) Posts Earnings Results

P3 Health Partners (NASDAQ:PIII) announced its earnings results on Monday. The company reported $0.07 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($3.96) by $4.03, FiscalAI reports. The business had revenue of $396.34 million for the quarter, compared to analyst estimates of $384.95 million.

Here are the key takeaways from P3 Health Partners’ conference call:

• P3 raised 2026 Adjusted EBITDA guidance to $90 million–$110 million, with the midpoint increasing to $100 million, after reporting $101 million year to date. However, Q3’s $21 million included about $12 million from favorable or non-cash items; underlying Q3 Adjusted EBITDA was approximately $10 million.
• Medical costs rose in Q3, particularly for outpatient and professional services, with greater pressure in Nevada. Management said it is targeting these costs, while noting normalized year-to-date Medicare Advantage medical expense remained 0.7% below full-year 2025 levels.
• Management reported stronger utilization and quality execution: outpatient prior-authorization effectiveness improved 68% from Q1, the inpatient-to-observation rate rose from 24% to 34%, and blood-pressure and diabetes control measures improved about nine points year over year.
• At-risk membership declined to approximately 105,000 from 116,000 a year earlier, primarily after P3 exited or reduced exposure to arrangements that did not meet its economic thresholds. The company also manages about 28,000 lives through services arrangements that it views as a potential source of future at-risk relationships.
• P3 identified more than $200 million in potential value creation across clinical execution, payer economics, and operating efficiency, primarily within its existing membership base. Management described this as a multi-year opportunity and plans to provide more detail on timing and earnings impact with its 2027 outlook.

P3 Health Partners Stock Up 6.2%

Shares of NASDAQ:PIII traded up $0.25 during midday trading on Monday, hitting $4.25. The stock had a trading volume of 15,080 shares, compared to its average volume of 408,876. The company’s 50-day moving average price is $6.13 and its 200-day moving average price is $6.57. P3 Health Partners has a fifty-two week low of $1.52 and a fifty-two week high of $16.89. The company has a market capitalization of $30.86 million, a P/E ratio of -0.13 and a beta of 1.81.

Wall Street Analyst Weigh In

PIII has been the subject of several recent research reports. Weiss Ratings reissued a “sell (d-)” rating on shares of P3 Health Partners in a research report on Tuesday, August 25th. Lake Street Capital restated a “buy” rating and set a $23.00 price objective on shares of P3 Health Partners in a research note on Tuesday, August 11th. One equities research analyst has rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $17.00.

P3 Health Partners Company Profile

P3 Health Partners Inc is a physician-led healthcare company focused on value-based care for Medicare Advantage beneficiaries. The company works with primary care physicians, specialists, health plans and community organizations to coordinate care and improve health outcomes while addressing patients’ medical and social needs.

Its services include primary care support, care coordination, chronic-condition management, preventive care, medication management and patient navigation. P3’s model uses an integrated care team and data-driven clinical programs to help physicians manage the health of senior populations across the care continuum.

Founded in 2017, P3 Health Partners became a publicly traded company in 2021 through a business combination with Foresight Acquisition Corp.